Agenus BOT+BAL Combination Posts 48% Three-Year Survival in Recurrent Ovarian Cancer
Agenus reports 48% estimated three-year survival with BOT+BAL in heavily pretreated recurrent ovarian cancer at IGCS 2026, with durable benefit observed between years two and three.
Does this change your view on the stock? Share your take below.
Read the full analysis on market.news
🇨🇦 Canada Stocks Earnings biotech pharma healthcare americas